ANRO (Alto Neuroscience) Accumulated Depreciation: $-1.89 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ANRO Alto Neuroscience Inc ANRO
12 GF Score
Price $36.30
! 2 Warning Signs
View Full Analysis

What is Alto Neuroscience Accumulated Depreciation?

Alto Neuroscience ANRO -0.63% 12 Accumulated Depreciation is $-1.89 Mil as of Jun. 2026. GuruFocus rates ANRO with a GF Score™ of 12/100. The stock has 2 warning signs investors should review.

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Alto Neuroscience's quarterly accumulated depreciation increased from Dec. 2025 ($-1.53 Mil) to Mar. 2026 ($-1.71 Mil) and increased from Mar. 2026 ($-1.71 Mil) to Jun. 2026 ($-1.89 Mil).

Alto Neuroscience's annual accumulated depreciation increased from Dec. 2023 ($-0.68 Mil) to Dec. 2024 ($-1.00 Mil) and increased from Dec. 2024 ($-1.00 Mil) to Dec. 2025 ($-1.53 Mil).

Alto Neuroscience Accumulated Depreciation Related Terms

Alto Neuroscience Accumulated Depreciation Historical Data

* Premium members only.

The historical data trend for Alto Neuroscience's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alto Neuroscience Accumulated Depreciation Chart

Alto Neuroscience Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Accumulated Depreciation
-0.24 -0.58 -0.68 -1.00 -1.53

Alto Neuroscience Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.32 -1.37 -1.53 -1.71 -1.89
ANRO
12GF Score
Alto Neuroscience Inc ANRO
Accumulated Depreciation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alto Neuroscience Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

What does a Accumulated Depreciation of $-1.89 Mil mean?
Alto Neuroscience (ANRO) has a Accumulated Depreciation of $-1.89 Mil as of Jun. 2026. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Alto Neuroscience and its competitors.
Is Alto Neuroscience's Accumulated Depreciation too high?
Alto Neuroscience's current Accumulated Depreciation is $-1.89 Mil. Overall, Alto Neuroscience has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Alto Neuroscience's Accumulated Depreciation compare to VOR and CGEM?
Alto Neuroscience's Accumulated Depreciation of $-1.89 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accumulated Depreciation for a Biotechnology company?
A good Accumulated Depreciation depends on the Biotechnology industry context. However, Accumulated Depreciation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accumulated Depreciation mean?
A high Accumulated Depreciation can signal that a stock is expensive relative to its fundamentals. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Alto Neuroscience and its competitors. Alto Neuroscience's current Accumulated Depreciation is $-1.89 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alto Neuroscience stock overvalued right now?
Alto Neuroscience (ANRO) has a current Accumulated Depreciation of $-1.89 Mil. The current Accumulated Depreciation is $-1.89 Mil. Alto Neuroscience's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accumulated Depreciation calculated?
Accumulated Depreciation is calculated from a company's financial statements. For Alto Neuroscience (ANRO), the current Accumulated Depreciation is $-1.89 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alto Neuroscience Business Description

Address 650 Castro Street, Suite 450, Mountain View, CA, USA, 94041
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
12GF Score

Get the complete analysis for ANRO

Accumulated Depreciation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$36.30
Price